Marimed INC 10-Q quarterly reports

MariMed Inc. filed its Q2 2026 10-Q, showing a 6.1% revenue increase to $41.9 million but a widening net loss to $3.6 million, alongside a significant tax benefit from the reclassification of cannabis under federal law.

MariMed Inc. reported a 4.2% increase in revenue for Q1 2026, reaching $39.5 million, while net loss attributable to common stockholders narrowed to $3.8 million.

MariMed Inc. reported a significant net loss in the third quarter of 2025 despite slight revenue growth, as it navigates strategic market exits and a substantial IRS tax liability.

MariMed Inc. reported a slight revenue decrease and a wider net loss for H1 2025, alongside an IRS tax lien and OTCQX listing compliance concerns.

MariMed Inc. reports flat revenue for Q1 2025 with a net loss, impacted by acquisition-related expenses and a bad debt expense.

MariMed Inc. reports a 4.6% increase in revenue for the third quarter of 2024 compared to the same period last year, driven by wholesale growth.

MariMed Inc. saw a 10.7% increase in revenue year-over-year in the second quarter of 2024, driven by wholesale growth, while also reporting a net loss.

MariMed Inc. saw a 10.3% increase in revenue in the first quarter of 2024 compared to the same period last year, driven by wholesale growth, while also reporting a net loss.